Jivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week. The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive […]